Baidu
map

FDA不建议COVID-19患者使用非甾体抗炎药(NSAID)

2020-03-20 Allan MedSci原创

FDA报道指出,使用非甾体抗炎药(NSAID)(如布洛芬)可能会使新型冠状病毒(COVID-19)肺炎恶化。

FDA报道指出,使用非甾体抗炎药(NSAID)(如布洛芬)可能会使新型冠状病毒(COVID-19)肺炎恶化。在2020年3月11日发表于《柳叶刀》的一项研究指出,NSAID可能加剧COVID-19肺炎患者的症状。

目前,FDA还不清楚将布洛芬等NSAID与COVID-19症状的恶化联系起来的科学证据。该机构正在进一步调查此问题,并将公布更多信息。对于那些希望使用NSAID以外的治疗选择的人,有多种非处方药(OTC)和处方药被批准用于缓解疼痛和减少发烧。

FDA建议公众在使用NSAID前应阅读完整的《药物概况》标签。当公众遵循标签上的指示和/或健康护理专业人员的指示时,OTC药物是安全有效的。使用处方药的患者应按照医疗保健专业人员的指示并按照标签上的说明服用这些药物。

 

原始出处:

https://www.firstwordpharma.com/node/1709518

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2033880, encodeId=097120338808c, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Tue Apr 14 08:32:35 CST 2020, time=2020-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081073, encodeId=2b5d20810e333, content=<a href='/topic/show?id=846b20389cd' target=_blank style='color:#2F92EE;'>#不建议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20389, encryptionId=846b20389cd, topicName=不建议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Fri May 01 15:32:35 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793596, encodeId=e4201e935965e, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Sun May 10 01:32:35 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297415, encodeId=f3a5129e415d7, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338707, encodeId=6d071338e07b2, content=<a href='/topic/show?id=afff99560c4' target=_blank style='color:#2F92EE;'>#非甾体抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99560, encryptionId=afff99560c4, topicName=非甾体抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346779, encodeId=14ab1346e7935, content=<a href='/topic/show?id=f20155404fc' target=_blank style='color:#2F92EE;'>#抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55404, encryptionId=f20155404fc, topicName=抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413649, encodeId=4fd114136495a, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
    2020-04-14 wjywjy
  2. [GetPortalCommentsPageByObjectIdResponse(id=2033880, encodeId=097120338808c, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Tue Apr 14 08:32:35 CST 2020, time=2020-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081073, encodeId=2b5d20810e333, content=<a href='/topic/show?id=846b20389cd' target=_blank style='color:#2F92EE;'>#不建议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20389, encryptionId=846b20389cd, topicName=不建议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Fri May 01 15:32:35 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793596, encodeId=e4201e935965e, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Sun May 10 01:32:35 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297415, encodeId=f3a5129e415d7, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338707, encodeId=6d071338e07b2, content=<a href='/topic/show?id=afff99560c4' target=_blank style='color:#2F92EE;'>#非甾体抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99560, encryptionId=afff99560c4, topicName=非甾体抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346779, encodeId=14ab1346e7935, content=<a href='/topic/show?id=f20155404fc' target=_blank style='color:#2F92EE;'>#抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55404, encryptionId=f20155404fc, topicName=抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413649, encodeId=4fd114136495a, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
    2020-05-01 周虎
  3. [GetPortalCommentsPageByObjectIdResponse(id=2033880, encodeId=097120338808c, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Tue Apr 14 08:32:35 CST 2020, time=2020-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081073, encodeId=2b5d20810e333, content=<a href='/topic/show?id=846b20389cd' target=_blank style='color:#2F92EE;'>#不建议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20389, encryptionId=846b20389cd, topicName=不建议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Fri May 01 15:32:35 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793596, encodeId=e4201e935965e, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Sun May 10 01:32:35 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297415, encodeId=f3a5129e415d7, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338707, encodeId=6d071338e07b2, content=<a href='/topic/show?id=afff99560c4' target=_blank style='color:#2F92EE;'>#非甾体抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99560, encryptionId=afff99560c4, topicName=非甾体抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346779, encodeId=14ab1346e7935, content=<a href='/topic/show?id=f20155404fc' target=_blank style='color:#2F92EE;'>#抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55404, encryptionId=f20155404fc, topicName=抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413649, encodeId=4fd114136495a, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
    2020-05-10 d830372
  4. [GetPortalCommentsPageByObjectIdResponse(id=2033880, encodeId=097120338808c, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Tue Apr 14 08:32:35 CST 2020, time=2020-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081073, encodeId=2b5d20810e333, content=<a href='/topic/show?id=846b20389cd' target=_blank style='color:#2F92EE;'>#不建议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20389, encryptionId=846b20389cd, topicName=不建议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Fri May 01 15:32:35 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793596, encodeId=e4201e935965e, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Sun May 10 01:32:35 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297415, encodeId=f3a5129e415d7, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338707, encodeId=6d071338e07b2, content=<a href='/topic/show?id=afff99560c4' target=_blank style='color:#2F92EE;'>#非甾体抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99560, encryptionId=afff99560c4, topicName=非甾体抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346779, encodeId=14ab1346e7935, content=<a href='/topic/show?id=f20155404fc' target=_blank style='color:#2F92EE;'>#抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55404, encryptionId=f20155404fc, topicName=抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413649, encodeId=4fd114136495a, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2033880, encodeId=097120338808c, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Tue Apr 14 08:32:35 CST 2020, time=2020-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081073, encodeId=2b5d20810e333, content=<a href='/topic/show?id=846b20389cd' target=_blank style='color:#2F92EE;'>#不建议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20389, encryptionId=846b20389cd, topicName=不建议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Fri May 01 15:32:35 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793596, encodeId=e4201e935965e, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Sun May 10 01:32:35 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297415, encodeId=f3a5129e415d7, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338707, encodeId=6d071338e07b2, content=<a href='/topic/show?id=afff99560c4' target=_blank style='color:#2F92EE;'>#非甾体抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99560, encryptionId=afff99560c4, topicName=非甾体抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346779, encodeId=14ab1346e7935, content=<a href='/topic/show?id=f20155404fc' target=_blank style='color:#2F92EE;'>#抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55404, encryptionId=f20155404fc, topicName=抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413649, encodeId=4fd114136495a, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2033880, encodeId=097120338808c, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Tue Apr 14 08:32:35 CST 2020, time=2020-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081073, encodeId=2b5d20810e333, content=<a href='/topic/show?id=846b20389cd' target=_blank style='color:#2F92EE;'>#不建议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20389, encryptionId=846b20389cd, topicName=不建议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Fri May 01 15:32:35 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793596, encodeId=e4201e935965e, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Sun May 10 01:32:35 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297415, encodeId=f3a5129e415d7, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338707, encodeId=6d071338e07b2, content=<a href='/topic/show?id=afff99560c4' target=_blank style='color:#2F92EE;'>#非甾体抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99560, encryptionId=afff99560c4, topicName=非甾体抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346779, encodeId=14ab1346e7935, content=<a href='/topic/show?id=f20155404fc' target=_blank style='color:#2F92EE;'>#抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55404, encryptionId=f20155404fc, topicName=抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413649, encodeId=4fd114136495a, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2033880, encodeId=097120338808c, content=<a href='/topic/show?id=852b216824' target=_blank style='color:#2F92EE;'>#AID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2168, encryptionId=852b216824, topicName=AID)], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=1072181, createdName=wjywjy, createdTime=Tue Apr 14 08:32:35 CST 2020, time=2020-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2081073, encodeId=2b5d20810e333, content=<a href='/topic/show?id=846b20389cd' target=_blank style='color:#2F92EE;'>#不建议#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20389, encryptionId=846b20389cd, topicName=不建议)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Fri May 01 15:32:35 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793596, encodeId=e4201e935965e, content=<a href='/topic/show?id=0a3c158509b' target=_blank style='color:#2F92EE;'>#SAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15850, encryptionId=0a3c158509b, topicName=SAID)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a244, createdName=d830372, createdTime=Sun May 10 01:32:35 CST 2020, time=2020-05-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297415, encodeId=f3a5129e415d7, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1338707, encodeId=6d071338e07b2, content=<a href='/topic/show?id=afff99560c4' target=_blank style='color:#2F92EE;'>#非甾体抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99560, encryptionId=afff99560c4, topicName=非甾体抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/1103841572/7F67E3BE360D6DD1D0A62E3E71E23CB6/100, createdBy=9d8a2500148, createdName=ms8888626721583891, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1346779, encodeId=14ab1346e7935, content=<a href='/topic/show?id=f20155404fc' target=_blank style='color:#2F92EE;'>#抗炎药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55404, encryptionId=f20155404fc, topicName=抗炎药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413649, encodeId=4fd114136495a, content=<a href='/topic/show?id=9209130645d' target=_blank style='color:#2F92EE;'>#NSAID#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13064, encryptionId=9209130645d, topicName=NSAID)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80342986042, createdName=amyloid, createdTime=Sun Mar 22 11:32:35 CST 2020, time=2020-03-22, status=1, ipAttribution=)]
    2020-03-22 amyloid

相关资讯

膀胱过度活动症的治疗取得新进展!FDA接受Vibegron的新药申请(NDA)

Urovant Sciences今日宣布,美国食品药品监督管理局(FDA)已接受该公司候选药物Vibegron的新药申请(NDA),以治疗膀胱过度活动症(OAB)患者的急迫性尿失禁、尿急和尿频的症状。

EHP的大麻双酚衍生物口服制剂EFDA-101治疗系统性硬化症,获得美国FDA的快速通道指定

Emerald Health Pharmaceuticals(EHP)临床主要候选产品EHP-101,获得了美国食品和药物管理局的快速通道认证,用于治疗系统性硬化症(SSc)。

Opdivo+Yervoy二线治疗肝细胞癌被FDA批准

3月11日,百时美施贵宝宣布FDA批准Opdivo(1mg/kg)+Yervoy(3mg/kg)用于治疗既往接受过索拉非尼治疗的肝细胞癌(HCC)患者。

库欣病新疗法:Isturisa(osilodrostat)获得美国FDA批准

美国FDA今日批准了Isturisa(osilodrostat)口服片剂用于治疗成人库欣氏病,这些成年患者要么不能进行垂体手术,要么已经进行了手术但仍然患有这种疾病。

Ponesimod治疗成人多发性硬化症:强生已向美国FDA提交新药申请(NDA)

强生制药公司今日宣布,已向美国食品和药品监督管理局(FDA)提交新药申请(NDA),以寻求Ponesimod治疗成人复发性多发性硬化症(MS)的上市许可。

美国FDA适应性设计指导原则的介绍

由于使用适应性设计可以加快药物研发的速度,更高效的利用研发资源,因此这种设计近年来受到国内外医药行业的重视。美国FDA于2010年颁布了《药物和生物制品临床试验适应性设计》指导原则草案,随着该方法的发

Baidu
map
Baidu
map
Baidu
map